Publications by authors named "Markus Jerling"

Claim this Profile
I
Insights on Nefecon, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy.
Jonathan Barratt, Jens Kristensen, Christian Pedersen, Markus Jerling

Drug Des Devel Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
Gunilla Huledal, Ana Ruiz-Garcia, Sonoko Kawakatsu, Xiaoning Wang, Per Sjöberg, Markus Jerling

J Clin Pharmacol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study.
Philip Van Damme, Petra Tilkin, Katarina Jansson Mercer, Joke Terryn, Ann D'Hondt, Markus Jerling

Brain Commun· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
Ugur Sahin, Martin Schuler, Heike Richly, Stefan Bauer, Anna Krilova, Markus Jerling

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Erik Lindström, Biljana Rizoska, Ian Henderson, Ylva Terelius, Markus Jerling

J Transl Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of intranasal kinetic oscillation stimulation on heart rate variability.
Markus Jerling, Iwona Cygankiewicz, Nabil Al-Tawil, Borje Darpo, Anders Ljungström

Ann Noninvasive Electrocardiol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Malin Wickström, Peter Nygren, Rolf Larsson, Johan Harmenberg, Jakob Lindberg, Markus Jerling

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria.
Norah Mwebaza, Markus Jerling, Lars L Gustafsson, Antero V Silva, Anton Pohanka

Basic Clin Pharmacol Toxicol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Michael Bergqvist, Georg Holgersson, Igor Bondarenko, Elena Grechanaya, Alexey Maximovich, Markus Jerling

Acta Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.
Simon Ekman, Johan Harmenberg, Jan-Erik Frödin, Stefan Bergström, Cecilia Wassberg, Markus Jerling

Acta Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Åke Berglund, Anders Ullén, Alla Lisyanskaya, Sergey Orlov, Hans Hagberg, Markus Jerling

Invest New Drugs· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Georg Holgersson, Stefan Bergström, Johan Harmenberg, Magnus Ringbom, Maria Klockare, Markus Jerling

Med Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.
Gesine Paul, Olof Zachrisson, Andrea Varrone, Per Almqvist, Markus Jerling

J Clin Invest· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.
Norah Mwebaza, Markus Jerling, Lars L Gustafsson, Celestino Obua, Paul Waako

Basic Clin Pharmacol Toxicol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.
Celestino Obua, Urban Hellgren, Muhammed Ntale, Lars L Gustafsson, Jasper W Ogwal-Okeng, Markus Jerling

Br J Clin Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of ranolazine.
Markus Jerling

Clin Pharmacokinet· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Markus Jerling, Hisham Abdallah

Clin Pharmacol Ther· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
Hisham Abdallah, Markus Jerling

J Clin Pharmacol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson.
Kenneth A Ellenbogen, Gearoid O'Neill, Eric N Prystowsky, John A Camm, Lixin Meng, Markus Jerling

Circulation· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.
Markus Jerling, Bee-Lian Huan, Kwan Leung, Nancy Chu, Hisham Abdallah

J Clin Pharmacol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.
Björn Hornestam, Markus Jerling, Mats O Karlsson, Peter Held,

Eur J Clin Pharmacol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis